I. Laszlovszky

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

Béla Kiss, Attila Horváth, Zsolt Némethy et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 358 citations

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

György Németh, I. Laszlovszky, Pál Czobor et al. · The Lancet · 2017 · 336 citations

Predominant Negative Symptoms, Psychiatry, Psychotic Disorder +8

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression

Suresh Durgam, Willie Earley, Alan Lipschitz et al. · American Journal of Psychiatry · 2015 · 202 citations · Full text

Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia

John M. Kane, Stephen R. Zukin, Yao Wang et al. · Journal of Clinical Psychopharmacology · 2015 · 176 citations

Drug Safety, Psychoactive Drug, Psychiatry +14

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial

Suresh Durgam, Anju Starace, Dayong Li et al. · Schizophrenia Research · 2014 · 174 citations · Full text